• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.440 -0.030 (-1.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
May 09, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 08, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
May 08, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 6, 2025 ↗
May 06, 2025
 
Via Benzinga
News headline image
Esperion Reports First Quarter 2025 Financial Results
May 06, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗
May 01, 2025
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
News headline image
Esperion to Participate in The Citizens Life Sciences Conference
April 25, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
April 24, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report First Quarter 2025 Financial Results on May 6
April 23, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
April 10, 2025
Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Appoints Robert E. Hoffman to Board of Directors
April 01, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
March 24, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
March 20, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 ↗
March 04, 2025
CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key... 
Via Stocktwits
News headline image
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
March 04, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 4, 2025 ↗
March 04, 2025
 
Via Benzinga
News headline image
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
March 03, 2025
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
February 18, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 13, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
January 09, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
December 18, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
December 13, 2024
 
Via Benzinga
News headline image
Esperion Announces $210 Million Convertible Debt Financing
December 13, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
December 12, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
December 02, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
November 26, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
November 21, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
November 18, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 08, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap